{"id":1603,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2018-09-27","marketCap":1859.862060546875,"name":"Arvinas Inc","phone":"12035351456","outstanding":55.029998779296875,"symbol":"ARVN","website":"https://www.arvinas.com/","industry":"Pharmaceuticals"},"price":33.7075,"year":2023,"month":12,"day":12,"weekday":"Tuesday","title":"Correlation between Arvinas Inc stock's performance and broader economic trends","date":"2023-12-12","url":"/posts/2023/12/12/ARVN","content":[{"section":"1. Market sentiment","text":"Arvinas Inc's stock performance can be influenced by overall market sentiment. During periods of positive economic outlook and market optimism, investors may be more willing to invest in riskier assets such as biotech stocks, leading to a potential increase in Arvinas Inc's stock price. Conversely, during periods of economic uncertainty or market downturns, investors may become more risk-averse, impacting the stock's performance."},{"section":"2. Funding availability","text":"Broader economic trends can affect the availability of funding for biotech companies like Arvinas Inc. In times of economic expansion, there may be increased funding opportunities and access to capital for research and development, which could positively impact the company's stock performance. In contrast, during economic downturns, funding may become scarce, making it more challenging for Arvinas Inc to secure necessary funds, potentially impacting their research and development efforts and stock performance."},{"section":"3. Investor confidence","text":"The overall economic environment and trends can influence investor confidence, which in turn can impact Arvinas Inc's stock performance. When the broader economy is performing well, investors may have higher confidence in the biotech industry as a whole, leading to increased interest and investment in Arvinas Inc. Conversely, economic downturns or negative economic indicators may erode investor confidence, leading to selling pressure and a decrease in stock price."},{"section":"4. Real-world example: COVID-19 pandemic","text":"The COVID-19 pandemic provides a real-world example of how broader economic trends can impact Arvinas Inc's stock performance. The pandemic caused significant disruptions to global economies, leading to market volatility and uncertainties. During the initial stages of the pandemic, Arvinas Inc's stock experienced a decline, along with many other stocks in the biotech industry. However, as the industry's role in developing vaccines and treatments became crucial, the stock rebounded, reflecting increased investor interest and positive sentiment towards the biotech sector."},{"section":"5. Real-world example: Economic expansion","text":"During periods of economic expansion, such as the post-financial crisis recovery, Arvinas Inc's stock performance demonstrated a positive correlation with broader economic trends. As the economy recovered and investor confidence improved, the company's stock price experienced significant growth. This can be attributed to increased funding availability, positive market sentiment, and investor interest in innovative biotech companies, aligning with the broader economic improvement."}],"tags":["CrossOver21","Long","Pharmaceuticals"],"news":[{"category":"company","date":1702036800,"headline":"Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session","id":124392149,"image":"","symbol":"ARVN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3248096526"},{"category":"company","date":1702028580,"headline":"Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday","id":124388769,"image":"","symbol":"ARVN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3247925808"},{"category":"company","date":1702025580,"headline":"Arvinas files to sell 16.39M shares of common stock for holders","id":124390959,"image":"","symbol":"ARVN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3247866502"},{"category":"company","date":1701927660,"headline":"Analysts Are Bullish on Top Healthcare Stocks: Veeva Systems (VEEV), Wuxi Biologics (Cayman) (WXIBF)","id":124367770,"image":"","symbol":"ARVN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3245760044"},{"category":"company","date":1701922320,"headline":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arvinas Holding Company (ARVN), Abbott Labs (ABT) and Owens \u0026 Minor (OMI)","id":124363380,"image":"","symbol":"ARVN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3245684349"},{"category":"company","date":1701914580,"headline":"Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Regeneron (REGN) and Arvinas Holding Company (ARVN)","id":124362059,"image":"","symbol":"ARVN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3245587882"},{"category":"company","date":1701879480,"headline":"Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study","id":124340216,"image":"https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","symbol":"ARVN","publisher":"Yahoo","summary":"Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.","url":"https://finance.yahoo.com/news/pfizer-pfe-arvinas-post-upbeat-161800950.html"},{"category":"company","date":1701866880,"headline":"Arvinas stock jumps 30% amid positive data for breast cancer drug","id":124369896,"image":"","symbol":"ARVN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244426204"},{"category":"company","date":1701863040,"headline":"ALT, SYRS and PHIO among mid-day movers","id":124336953,"image":"","symbol":"ARVN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244330252"},{"category":"company","date":1701862380,"headline":"12 Health Care Stocks Moving In Wednesday's Intraday Session","id":124338947,"image":"","symbol":"ARVN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244316922"},{"category":"company","date":1701859560,"headline":"Buy Rating Affirmed for Arvinas Holding Company on Strong Clinical Data and Therapeutic Potential","id":124369902,"image":"","symbol":"ARVN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244249884"},{"category":"company","date":1701857220,"headline":"Arvinas upgraded to Buy at Jefferies after vepdegestrant combo data reported","id":124333197,"image":"","symbol":"ARVN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244194298"},{"category":"company","date":1701856680,"headline":"Jefferies gets more bullish on Arvinas, upgrades shares","id":124333198,"image":"","symbol":"ARVN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244180955"},{"category":"company","date":1701856380,"headline":"THOR Industries Reports Upbeat Earnings, Joins Dave \u0026 Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday","id":124333015,"image":"","symbol":"ARVN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244174973"},{"category":"company","date":1701854027,"headline":"Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib and Plans to Expand Vepdegestrant Development Program","id":124330567,"image":"","symbol":"ARVN","publisher":"Finnhub","summary":"NEW HAVEN - Arvinas, Inc. and Pfizer Inc. today announced clinical data for vepdegestrant , a novel oral PROteolysis TArgeting Chimera estrogen receptor degrader, in combination with palbociclib...","url":"https://finnhub.io/api/news?id=203226eff00ceb4561270ce0627dd685a3b9ff76bec6d08dc666172bc36cd543"},{"category":"company","date":1701849120,"headline":"Arvinas, Pfizer Plan To Broaden Development Of Breast Cancer Candidate","id":124332577,"image":"","symbol":"ARVN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244015125"},{"category":"company","date":1701848040,"headline":"Arvinas price target raised to $33 from $24 at Wedbush","id":124333201,"image":"","symbol":"ARVN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3243993224"},{"category":"company","date":1701834720,"headline":"Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program","id":124327511,"image":"https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081","symbol":"ARVN","publisher":"Yahoo","summary":"NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc. (NYSE: PFE) to discuss vepdegestrant (ARV-471) data presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) as well as plans to expand the vepdegestrant development program. Investor Call \u0026 W","url":"https://finance.yahoo.com/news/arvinas-host-conference-call-webcast-035200504.html"},{"category":"company","date":1701827220,"headline":"Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session","id":124339785,"image":"","symbol":"ARVN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244515708"},{"category":"company","date":1701824760,"headline":"Jefferies upgrades Arvinas to buy in wake of positive ARV-471 data","id":124369906,"image":"","symbol":"ARVN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244452468"},{"category":"company","date":1701801180,"headline":"Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program","id":124320524,"image":"https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081","symbol":"ARVN","publisher":"Yahoo","summary":"– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the potential of vepdegestrant in combination with palbociclib (IBRANCE®) – – Tolerability generally consistent with the profile of palbociclib and what has been observed in other clinical trials of vepdegestrant– – Pending additional data and agreement with regulatory authorities, Arvinas and Pfizer pla","url":"https://finance.yahoo.com/news/arvinas-pfizer-announce-interim-data-183300772.html"},{"category":"company","date":1701780120,"headline":"Arvinas, Pfizer report interim data from trial of vepdegestrant with palbociclib","id":124321208,"image":"","symbol":"ARVN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242551258"},{"category":"company","date":1701442511,"headline":"Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect?","id":124240428,"image":"https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295","symbol":"ARVN","publisher":"Yahoo","summary":"The average of price targets set by Wall Street analysts indicates a potential upside of 145.5% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.","url":"https://finance.yahoo.com/news/does-arvinas-inc-arvn-potential-145511974.html"},{"category":"company","date":1701325860,"headline":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Treace Medical Concepts (TMCI), Arvinas Holding Company (ARVN) and Cooper Co (COO)","id":124200978,"image":"","symbol":"ARVN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3234913569"},{"category":"company","date":1701209100,"headline":"Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium","id":124161081,"image":"https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081","symbol":"ARVN","publisher":"Yahoo","summary":"-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) -- NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant is a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrog","url":"https://finance.yahoo.com/news/arvinas-pfizer-announce-updated-vepdegestrant-220500760.html"},{"category":"company","date":1701151483,"headline":"Arvinas Announces Oversubscribed $350 Million Private Placement","id":124137810,"image":"","symbol":"ARVN","publisher":"Finnhub","summary":"NEW HAVEN - Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has entered into a securities purchase...","url":"https://finnhub.io/api/news?id=395920ccdfa4d5a069d892405f8d7109c81c2003e59d20af552ad2c56918f341"},{"category":"company","date":1701144480,"headline":"Arvinas, Pfizer announce updated Vepdegestrant data to be presented at SABCS","id":124169293,"image":"","symbol":"ARVN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3232089074"}]}